These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 31795192)

  • 1. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.
    Li H; Zhang J; Tong JHM; Chan AWH; Yu J; Kang W; To KF
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different mutation profiles associated to P53 accumulation in colorectal cancer.
    López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M
    Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.
    Li XL; Zhou J; Chen ZR; Chng WJ
    World J Gastroenterol; 2015 Jan; 21(1):84-93. PubMed ID: 25574081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors.
    Sakai E; Fukuyo M; Matsusaka K; Ohata K; Doi N; Takane K; Matsuhashi N; Fukushima J; Nakajima A; Kaneda A
    Cancer Sci; 2016 Jun; 107(6):820-7. PubMed ID: 26991699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
    Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
    Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.
    Alam SK; Yadav VK; Bajaj S; Datta A; Dutta SK; Bhattacharyya M; Bhattacharya S; Debnath S; Roy S; Boardman LA; Smyrk TC; Molina JR; Chakrabarti S; Chowdhury S; Mukhopadhyay D; Roychoudhury S
    Cell Death Differ; 2016 Apr; 23(4):707-22. PubMed ID: 26494468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-300 promotes proliferation and EMT-mediated colorectal cancer migration and invasion by targeting p53.
    Wang L; Yu P
    Oncol Rep; 2016 Dec; 36(6):3225-3232. PubMed ID: 27779716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.
    Iacopetta B; Russo A; Bazan V; Dardanoni G; Gebbia N; Soussi T; Kerr D; Elsaleh H; Soong R; Kandioler D; Janschek E; Kappel S; Lung M; Leung CS; Ko JM; Yuen S; Ho J; Leung SY; Crapez E; Duffour J; Ychou M; Leahy DT; O'Donoghue DP; Agnese V; Cascio S; Di Fede G; Chieco-Bianchi L; Bertorelle R; Belluco C; Giaretti W; Castagnola P; Ricevuto E; Ficorella C; Bosari S; Arizzi CD; Miyaki M; Onda M; Kampman E; Diergaarde B; Royds J; Lothe RA; Diep CB; Meling GI; Ostrowski J; Trzeciak L; Guzinska-Ustymowicz K; Zalewski B; Capellá GM; Moreno V; Peinado MA; Lönnroth C; Lundholm K; Sun XF; Jansson A; Bouzourene H; Hsieh LL; Tang R; Smith DR; Allen-Mersh TG; Khan ZA; Shorthouse AJ; Silverman ML; Kato S; Ishioka C;
    Ann Oncol; 2006 May; 17(5):842-7. PubMed ID: 16524972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients.
    Hassin O; Nataraj NB; Shreberk-Shaked M; Aylon Y; Yaeger R; Fontemaggi G; Mukherjee S; Maddalena M; Avioz A; Iancu O; Mallel G; Gershoni A; Grosheva I; Feldmesser E; Ben-Dor S; Golani O; Hendel A; Blandino G; Kelsen D; Yarden Y; Oren M
    Nat Commun; 2022 May; 13(1):2800. PubMed ID: 35589715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
    Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
    Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma.
    Javier BM; Yaeger R; Wang L; Sanchez-Vega F; Zehir A; Middha S; Sadowska J; Vakiani E; Shia J; Klimstra D; Ladanyi M; Iacobuzio-Donahue CA; Hechtman JF
    Oncotarget; 2016 Aug; 7(32):50875-50882. PubMed ID: 27248473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues
    Xue Y; Barker N; Hoon S; He P; Thakur T; Abdeen SR; Maruthappan P; Ghadessy FJ; Lane DP
    Cancer Res; 2019 Jul; 79(14):3595-3607. PubMed ID: 31138526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
    Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
    Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer.
    Choi TG; Nguyen MN; Kim J; Jo YH; Jang M; Nguyen NNY; Yun HR; Choe W; Kang I; Ha J; Tang DG; Kim SS
    J Pathol; 2018 Sep; 246(1):115-126. PubMed ID: 29876924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.